Immunovant, Inc. today announced its financial results for the fiscal first quarter ended June 30, 2025, along with updates on its clinical development programs. The company reported a net loss of $120.6 million, or $0.71 per common share, for the quarter, compared to a net loss of $87.2 million, or $0.60 per common share, for the same period in the prior fiscal year. Research and development expenses increased to $101.2 million from $75.5 million year-over-year, primarily due to IMVT-1402 clinical trials and contract manufacturing costs.
As of June 30, 2025, Immunovant's cash and cash equivalents stood at approximately $598.9 million, which is expected to provide a financial runway through the Graves' Disease readout anticipated in 2027. This liquidity supports the ongoing and planned clinical trials for its lead asset, IMVT-1402.
In June 2025, Immunovant initiated a second potentially registrational trial evaluating IMVT-1402 in Graves' Disease (GD) and a potentially registrational trial for IMVT-1402 in Sjögren’s Disease (SjD). All clinical development timelines remain on track for IMVT-1402 across its six announced indications. The company expects to report remission data from the batoclimab proof-of-concept study in GD at the American Thyroid Association (ATA) Annual Meeting in September 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.